Literature DB >> 31604819

Characterization of the internal translation initiation region in monoclonal antibodies expressed in Escherichia coli.

Erik M Leith1, William B O'Dell1,2, Na Ke3, Colleen McClung3, Mehmet Berkmen3, Christina Bergonzo2, Robert G Brinson2, Zvi Kelman4,2.   

Abstract

Monoclonal antibodies (mAbs) represent an important platform for the development of biotherapeutic products. Most mAbs are produced in mammalian cells, but several mAbs are made in Escherichia coli, including therapeutic fragments. The NISTmAb is a well-characterized reference material made widely available to facilitate the development of both originator biologics and biosimilars. Here, when expressing NISTmAb from codon-optimized constructs in E. coli (eNISTmAb), a truncated variant of its heavy chain was observed. N-terminal protein sequencing and mutagenesis analyses indicated that the truncation resulted from an internal translation initiation from a GTG codon (encoding Val) within eNISTmAb. Using computational and biochemical approaches, we demonstrate that this translation initiates from a weak Shine-Dalgarno sequence and is facilitated by a putative ribosomal protein S1-binding site. We also observed similar internal initiation in the mAb adalimumab (the amino acid sequence of the drug Humira) when expressed in E. coli Of note, these internal initiation regions were likely an unintended result of the codon optimization for E. coli expression, and the amino acid pattern from which it is derived was identified as a Pro-Ser-X-X-X-Val motif. We discuss the implications of our findings for E. coli protein expression and codon optimization and outline possible strategies for reducing the likelihood of internal translation initiation and truncated product formation.

Entities:  

Keywords:  Escherichia coli (E. coli); GTG codon; NISTmAb; Shine-Dalgarno sequence; codon optimization; mAb; monoclonal antibody; protein expression; recombinant protein expression; translation initiation; translation regulation

Mesh:

Substances:

Year:  2019        PMID: 31604819      PMCID: PMC6885640          DOI: 10.1074/jbc.RA119.011008

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  The complete genome sequence of Escherichia coli K-12.

Authors:  F R Blattner; G Plunkett; C A Bloch; N T Perna; V Burland; M Riley; J Collado-Vides; J D Glasner; C K Rode; G F Mayhew; J Gregor; N W Davis; H A Kirkpatrick; M A Goeden; D J Rose; B Mau; Y Shao
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

2.  Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

Authors:  Laura C Simmons; Dorothea Reilly; Laura Klimowski; T Shantha Raju; Gloria Meng; Paul Sims; Kyu Hong; Robert L Shields; Lisa A Damico; Patricia Rancatore; Daniel G Yansura
Journal:  J Immunol Methods       Date:  2002-05-01       Impact factor: 2.303

3.  Single mutation in Shine-Dalgarno-like sequence present in the amino terminal of lactate dehydrogenase of Plasmodium effects the production of an eukaryotic protein expressed in a prokaryotic system.

Authors:  Mustafa Cicek; Ozal Mutlu; Aysegul Erdemir; Ebru Ozkan; Yunus Saricay; Dilek Turgut-Balik
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

Review 4.  Certolizumab pegol.

Authors:  Niti Goel; Sue Stephens
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

5.  Optimized expression of full-length IgG1 antibody in a common E. coli strain.

Authors:  Conrad En Zuo Chan; Angeline Pei Chiew Lim; Annie Hoi Yi Chan; Paul A MacAry; Brendon John Hanson
Journal:  PLoS One       Date:  2010-04-20       Impact factor: 3.240

6.  Ribosomal protein S1 is required for translation of most, if not all, natural mRNAs in Escherichia coli in vivo.

Authors:  M A Sørensen; J Fricke; S Pedersen
Journal:  J Mol Biol       Date:  1998-07-24       Impact factor: 5.469

7.  ViennaRNA Package 2.0.

Authors:  Ronny Lorenz; Stephan H Bernhart; Christian Höner Zu Siederdissen; Hakim Tafer; Christoph Flamm; Peter F Stadler; Ivo L Hofacker
Journal:  Algorithms Mol Biol       Date:  2011-11-24       Impact factor: 1.405

8.  Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria.

Authors:  Michael-Paul Robinson; Na Ke; Julie Lobstein; Cristen Peterson; Alana Szkodny; Thomas J Mansell; Corinna Tuckey; Paul D Riggs; Paul A Colussi; Christopher J Noren; Christopher H Taron; Matthew P DeLisa; Mehmet Berkmen
Journal:  Nat Commun       Date:  2015-08-27       Impact factor: 14.919

9.  SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm.

Authors:  Julie Lobstein; Charlie A Emrich; Chris Jeans; Melinda Faulkner; Paul Riggs; Mehmet Berkmen
Journal:  Microb Cell Fact       Date:  2012-05-08       Impact factor: 5.328

10.  A new and updated resource for codon usage tables.

Authors:  John Athey; Aikaterini Alexaki; Ekaterina Osipova; Alexandre Rostovtsev; Luis V Santana-Quintero; Upendra Katneni; Vahan Simonyan; Chava Kimchi-Sarfaty
Journal:  BMC Bioinformatics       Date:  2017-09-02       Impact factor: 3.169

View more
  3 in total

Review 1.  Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.

Authors:  Md Harunur Rashid
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

2.  Active human full-length CDKL5 produced in the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125.

Authors:  Andrea Colarusso; Concetta Lauro; Marzia Calvanese; Ermenegilda Parrilli; Maria Luisa Tutino
Journal:  Microb Cell Fact       Date:  2022-10-14       Impact factor: 6.352

3.  Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions.

Authors:  Marine Lénon; Na Ke; Cecily Szady; Hassan Sakhtah; Guoping Ren; Bruno Manta; Bryce Causey; Mehmet Berkmen
Journal:  Appl Microbiol Biotechnol       Date:  2020-09-30       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.